Sign in →

Test ID FLFFT Liver Fibrosis, Fibro Test-ActiTest Panel

Method Name

Nephelometry and Spectrophotometry

Reporting Name

Liver Fibrosis, FibroTest

Specimen Type

Serum

Draw blood in a plain red-top tube(s), serum gel tube(s) is acceptable. Spin down and send 3.5 mL of serum frozen in a plastic screw-capped vial.

 

Note:    1. Overnight fast is preferred.

            2. Not available for patients less than 2 years of age.

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 5 days
  Refrigerated  5 days
  Ambient  24 hours

Reference Values

Test

Reference Range

Fibrosis Score

No reference range available

Fibrosis Stage

No reference range available

Fibrosis Interpretation

FibroTest Score

Metavir Score

 

0.00-0.21

F0 no fibrosis

 

0.22-0.27

F0-F1

 

0.28-0.31

F1 minimal fibrosis

 

0.32-0.48

F1-F2

 

0.49-0.58

F2 moderate fibrosis

 

0.59-0.72

F3 advanced fibrosis

 

0.73-0.74

F3-F4

 

0.75-1.00

F4 severe fibrosis

Necroinflammat Act Score

No reference range available

Necroinflammat Act Grade

No reference range available

Necroinflammat Interp

ActiTest Score

Metavir Score

0.00-0.17

A0 no activity

0.18-0.29

A0-A1

0.30-0.36

A1 minimal activity

0.37-0.52

A1-A2

0.53-0.60

A2 significant activity

0.61-0.62

A2-A3

0.63-1.00

A3 severe activity

Alpha-2-Macroglobins

<18 Years: Not established

≥18 Years: 106-279 mg/dL

Haptoglobin

<18 Years: Not established

≥18 Years: 43-212 mg/dL

Apolioprotein A-1

Males:

<18 Years: Not established

≥18 Years: 94-176 mg/dL

Females:

<18 Years: Not established

≥18 Years: 101-198 mg/dL

Total Bilirubin

2-9 Years: 0.2-0.8 mg/dL

10-19 Years: 0.2-1.1 mg/dL

≥20 Years: 0.2-1.2 mg/dL

GGT

Males:

2-12 Years: 3-22 U/L

13-15 Years: 8-32 U/L

16-19 Years: 9-31 U/L

20-29 Years: 3-70 U/L

30-39 Years: 3-90 U/L

40-54 Years: 3-95 U/L

55-59 Years: 3-85 U/L

≥60 Years: 3-70 U/L

Females:

2-12 Years: 3-22 U/L

13-15 Years: 7-18 U/L

16-19 Years: 6-26 U/L

20-29 Years: 3-40 U/L

30-39 Years: 3-50 U/L

40-49 Years: 3-55 U/L

50-59 Years: 3-70 U/L

≥60 Years: 3-65 U/L

Alanine Aminotransferase (ALT)

Males:

2-3 Years: 5-30 U/L

4-12 Years: 8-30 U/L

13-15 Years: 7-32 U/L

16-19 Years: 8-46 U/L

≥20 Years: 9-46 U/L

Females:

2-3 Years: 5-30 U/L

4-12 Years: 8-24 U/L

13-15 Years: 5-32 U/L

16-19 Years: 5-32 U/L

≥20 Years: 6-29 U/L

 

The reliability of results is dependent on compliance with the pre-analytical and analytical conditions recommended by BioPredictive. The Tests have to be deferred for: acute hemolysis, acute hepatitis, acute inflammation, extra hepatic cholestasis. The advice of a specialist should be sought for interpretation in chronic hemolysis and Gilbert's syndrome. The Test interpretation is not validated in liver transplant patients. Isolated extreme values of one of the components should lead to caution in interpreting the results. In case of discordance between a biopsy result and a Test, it is recommended to seek the advice of a specialist. The cause of these discordances could be due to a flaw of the Test or to a flaw in the biopsy: i.e. a liver biopsy has a 33% variability rate for one fibrosis stage. FibroTest is interpretable for chronic hepatitis B and C, alcoholic and non-alcoholic steatosis. ActiTest is interpretable for chronic hepatitis B and C.

Day(s) Performed

Tuesday through Saturday

Report Available

2 - 4 days

Performing Laboratory

Quest Diagnostics Nichols Institute

Test Classification

The performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. It has not been cleared or approved by the U.S. Food and Drug Administration. Performance characteristics refer to the analytical performance of the test.

CPT Code Information

82172

82247

82977

83010

83883

84460

NY State Approved

Yes